Carisma Therapeutics

Steven Kelly, CEO

Oct. 10 | 4:30pm | Ecolab Life Sciences Ballroom 

Philadelphia, PA


Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions